Engineering Cardiac Troponin C: Potential Therapeutic for Heart Failure  by Shettigar, Vikram et al.
596a Wednesday, February 11, 2015Key Findings: Pargyline increased dialysate 5-HT concentration from 1.85 0.3
at baseline to 3.95 0.5 nM but decreased dialysate 5-HIAA concentration from
20.75 1.0 at baseline to 15.85 1.4 nM at 60-80 min of administration. Fluox-
etine increased dialysate 5-HT concentration from 1.95 0.4 at baseline to 6.55
0.9 nM at 60-80 min of administration, but did not change dialysate 5-HIAA
concentration. Local administration of ADP (100 mM) increased dialysate 5-
HT and 5-HIAA concentrations. Pargyline did not affect ADP-induced increase
in dialysate 5-HT concentration but suppressed ADP-induced increase in dialy-
sate 5-HIAA concentration during 60 min of ADP administration. Fluoxetine
increased dialysate 5-HT concentration at 40-60 min of ADP administration,
but did not affect ADP-induced increase in dialysate 5-HIAA concentration.
Significance: Simultaneous monitoring of myocardial interstitial 5-HT and
5-HIAA levels provides valuable information on 5-HT kinetics including reup-
take and enzymatic degradation by MAO, which play a role in the regulation
of myocardial interstitial 5-HT levels at baseline and when 5-HT levels are
elevated.
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The therapeutic effect of ghrelin has been reported in humans as well as in an-
imal models of chronic heart failure. However, little is known about the thera-
peutic efficacy of ghrelin for the treatment of inherited forms of dilated
cardiomyopathy (DCM). We aim to examine whether ghrelin is beneficial for
the treatment of inherited DCM with a deletion mutation DK210 in the cardiac
troponin T (cTnT) gene using a knock-in mouse model. Ghrelin (150 mg/kg/day)
was administered subcutaneously to the mouse model of inherited DCM.
The therapeutic effects were examined on the basis of survival and myocardial
remodeling. Ghrelin administration prolonged the life span of DCM mice
compared to the saline-treated controls. Echocardiography data showed that
ghrelin reduced left ventricular (LV) end-diastolic dimensions and increased
LV ejection fraction. Moreover, histoanatomical data revealed that ghrelin
decreased the heart-to-body weight ratio, prevented cardiac remodeling and
fibrosis, and markedly decreased the expression of brain natriuretic peptide.
Telemetry recording and heart rate variability analysis showed that ghrelin sup-
pressed the excessive cardiac sympathetic nerve activity (CSNA) and recovered
the cardiac parasympathetic nerve activity. Ghrelin has therapeutic benefits for
the treatment of DCMwith DK210 mutation in cTnT. Importantly, these cardio-
vascular benefits of ghrelin are likely linked to the suppression of CSNA and
recovery of cardiac parasympathetic nerve activity.
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The N-terminal extension (NTE; residues 42-73) of mouse cardiac troponin T
(TnT) desensitizes cardiac myofilaments to Ca2þ by stabilizing thin filaments
in the blocked-state.We arrived at this conclusion using detergent-skinnedmus-
cle from transgenic (TG)mouse hearts that expressed 54%of chimeric TnT (res-
idues 1-73 of mouse cardiac TnT were replaced by residues 1-41 of mouse fast
skeletal TnT). Here, we extended our investigation to include higher dose effects
of the modified TnT on cardiac myofilament function/phenotype using
detergent-skinned fiber studies and echocardiography measurements in two
different TG mouse lines (TG-55 and TG-64 that expressed 55% and 64% of
chimeric TnT, respectively). Both TG-55 and TG-64 mice showed a similar in-
crease in myofilament Ca2þ sensitivity at sarcomere lengths (SL) of 1.9 and 2.3
mm. However, Ca2þ-activated maximal tension increased significantly only in
TG-64 mice at either SL. There was a progressive decrease in the overall heartsize andheart-to-bodyweight ratios in bothTG-55 andTG-64mice. Left ventric-
ular diastolic functional parameters (isovolumic relaxation time and E-wave
deceleration time) showed a graded increase in TG-55 and TG-64 mice; how-
ever, such effects were only significant in TG-64 mice, suggesting impaired
relaxation. Systolic functional parameters (stroke volume, ejection fraction
and fractional shortening) were unaffected in TG-55 mice, but significantly
decreased in TG-64 mice. Thus, higher levels of chimeric TnT (64%) depressed
both diastolic and systolic function significantly in TG-64mice.Wewill discuss
the link between the effects of the modified N-terminus of TnT on cardiac
myofilament function and the resultant pathological remodeling of the heart.
Our findings have pathological relevance because a growing number of
disease-related mutations are found both in and near the NTE of cardiac TnT.
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The primary structure of the H1-helix of troponin T (TnT) varies among different
types of striated muscles. Moreover, these muscles also express different myosin
heavy chain (MHC) isoforms. Recently, we demonstrated that pseudo-phosphor-
ylation of residue 204 (near the H1-helix) of cardiac TnT affected the functional
state of the thin filament differently in fibers that expressed either a- or b-MHC
isoforms (Michael et al., Basic Res Cardiol, 109:442, 2014). In this follow-up
study, we investigated how the isoform-specific function of the H1-helix of car-
diac TnT was influenced by a- and b-MHC isoforms. We generated a mutant
rat cardiac TnT (RfsH1) in which the cardiac H1-helix was replaced by the fast
skeletal H1-helix. Recombinant RfsH1 was reconstituted into detergent-skinned
cardiac muscle fibers from either normal rats (expressing a-MHC) or propylth-
iouracil treated rats (expressing b-MHC). Steady-state and dynamic measure-
ments were carried out at sarcomere length 2.3 mm. Our results demonstrated
that RfsH1 decreased Ca2þ-activated maximal ATPase activity differently in
a-MHC (~33%) and b-MHC (~17%) fibers. Furthermore, RfsH1 decreased ten-
sion cost (~31%) and crossbridge (XB) distortion dynamics (~25%) in a-MHC
but not in b-MHC fibers. Because the above mentioned parameters are indices
of the rate of XB detachment, our results suggest that the interplay between the
RfsH1- and a-MHC-mediated effects on the thin filament modulates XB detach-
ment kinetics. Our findings suggest that the conformational changes in the H1-
helix of TnT are sensitive toMHC isoform-mediated changes in the thin filament.
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We have engineered cardiac TnCs with increased (L48Q) or decreased (D73N)
Ca2þ sensitivity. To express these proteins in the in vivo heart we utilized an
adeno-associated virus serotype 9 (AAV-9). The Ca2þ desensitized D73N
TnC recapitulated a dilated cardiomyopathy phenotype and depressed function
as observed by echocardiography and isolated cardiomyocytes. On the other
hand, AAV-9 containing the Ca2þ sensitized L48Q TnC did not cause any
disease phenotype or arrhythmias commonly associated with increased myofil-
ament Ca2þ sensitivity. In healthy mice, L48Q TnC increased myocyte contrac-
tion and whole heart contractility with improved cardiovascular performance
(increased V02max). Excitingly, L48Q TnC expressing mice were able to pre-
serve higher contractility, ejection fraction, cardiac performance and decreased
death rate even after undergoing trans-aortic constriction or myocardial in-
farction. Additionally, L48Q TnC was able to increase contractility, ejection
fraction and cardiac performance in mice which expressed L48Q TnC after
having a myocardial infarction. In summary, engineered TnCs show potential
to be used as treatment strategies against different cardiomyopathies.
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Calcium binding to and dissociation from cardiac troponin C (TnC) are essential
steps leading to cardiac muscle contraction/relaxation. It is well documented
that the calcium binding properties of TnC are not constant, but are sensitive to
complex interactions between the additional thin and even thick filament proteins.
There is a growing body of evidence that protein modifications/mutations within
